
WHAT IS CLAIMED IS:


1. A compound of formula 1.0:



(1.0)

or a pharmaceutically acceptable salt or solvate thereof, wherein R^1, R^2 and Q are independently selected, and wherein:

Q is:



R^1 is selected from the group consisting of: heteroaryl and substituted heteroaryl, wherein said substituted heteroaryl is substituted with 1 to 3 substituents independently selected from the group consisting of: -OH, alkoxy, and –O-alkylene-O-alkyl;

R^2 is selected from the group consisting of: -O-alkyl and -S-alkyl; and

R^5 is selected from the group consisting of:

(a) triazolyl-phenyl-,

(b) triazolyl-phenyl- wherein said phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: halo and alkoxy,

(c) substituted triazolyl-phenyl- wherein said phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: halo and alkoxy, and said triazolyl group is substituted with one or two substitutents independently selected from the group consisting of: alkyl, hydroxy substituted alkyl, -alkylene-O-alkyl, and amino,

(d) triazolyl-thienyl-,

(e) triazolyl-thienyl- wherein said thienyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of: halo and alkoxy,

(f) substituted triazolyl-thienyl- wherein said thienyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of: halo and

alkoxy, and said triazolyl group is substituted with one or two substitutents independently selected from the group consisting of: alkyl, hydroxy substituted alkyl, -alkylene-O-alkyl, and amino,

(g) triazolyl-pyridyl-,

(h) triazolyl-pyridyl- wherein said pyridyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: halo, alkyl, and alkoxy, provided that the carbon atoms adjacent to the nitrogen atom in said pyridyl are not substituted with halo, and

(i) substituted triazolyl-pyridyl- wherein: (1) said pyridyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: halo, alkyl, and alkoxy, provided that the carbon atoms adjacent to the nitrogen atom in said pyridyl are not substituted with halo, and (2) said triazolyl group is substituted with one or two substitutents independently selected from the group consisting of: alkyl, hydroxy substituted alkyl, -alkylene-O-alkyl, and amino,

(j) triazolyl-thiazolyl-,

(k) triazolyl-thiazolyl- wherein said thiazolyl is optionally substituted with 1 substituent independently selected from the group consisting of: halo, alkyl, and alkoxy, amino, alkylamino, and dialkylamino wherein each alkyl is independently selected, and

(l) substituted triazolyl-thiazolyl- wherein (1) said thiazolyl is optionally substituted with 1 substituent independently selected from the group consisting of: halo, alkyl, and alkoxy, amino, alkylamino, and dialkylamino wherein each alkyl is independently selected, and (2) said triazolyl group is substituted with one or two substitutents independently selected from the group consisting of: alkyl, hydroxy substituted alkyl, -alkylene-O-alkyl, and amino,

(m) pyridazinyl-thienyl-,

(n) pyridazinyl-thienyl- wherein said thienyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of: halo and alkoxy, and

(o) substituted pyridazinyl-thienyl- wherein (1) said thienyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of: halo and alkoxy, and (2) said pyridazinyl group is substituted with 1 to 3 substitutents independently selected from the group consisting of: =O, alkyl, amino, alkylamino, dialkylamino wherein each alkyl is independently selected, and halo,


provided that the carbon atoms adjacent to the nitrogen atoms in said pyridazinyl are not substituted with halo, and


provided that when said -alkylene-O-alkyl group is bound to the nitrogen of said triazolyl in (c), (f), (i) and (l) of R^5 the alkylene moiety of said -alkylene-O-alkyl group is not $-CH_2-$.


2. The compound of Claim 1 wherein R^1 is a pyridyl substituted with a substituent selected from the group consisting of: -OH, alkoxy, and –O-alkylene-O-alkyl.

3. The compound of Claim 2 wherein said substituent is selected from the group consisting of: $-O-CH_3$, $-O-C_2H_5$, $-O-CH(CH_3)_2$, and $-O-(CH_2)_2-O-CH_3$.

4. The compound of Claim 1 wherein R^1 is selected from the group consisting of:



,


, and


.

5. The compound of Claim 1 wherein R^2 is selected from the group consisting of: $-OCH_3$ and $-SCH_3$.

6. The compound of Claim 1 wherein R^6 is selected from the group consisting of:

(a) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted with one or two alkyl groups selected from the group consisting of: $-C_1-C_6$alkyl, $-C_1-C_4$alkyl, $-C_1-C_2$alkyl, and $-CH_3$;

(b) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted with one or two alkyl groups selected from the group consisting of: $-C_1-C_4$alkyl, $-C_1-C_2$alkyl, and $-CH_3$;

(c) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with an alkyl group selected from the group consisting of: -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(d) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with an -alkylene-O-alkyl group selected from the group consisting of: -C_2-C_4alkylene-O-C_1-C_6alkyl, -C_2alkylene-O-C_1-C_2alkyl, -C_2-C_4alkylene-O-CH_3, and –$CH_2CH_2OCH_3$;

(e) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with an -alkylene-O-alkyl group selected from the group consisting of: -C_2alkylene-O-C_1-C_2alkyl, and –$CH_2CH_2OCH_3$;

(f) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with a hydroxy substituted alkyl group selected from the group consisting of: hydroxy substituted -C_1-C_4alkyl, hydroxy substituted -C_1-C_2alkyl, and hydroxy substituted -CH_3; and

(g) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with a hydroxy substituted alkyl group selected from the group consisting of: $CH_2COH(CH_3)_2$, and -CH_2CH_2OH.

7. The compound of Claim 1 wherein the optional halo substituents for the phenyl moiety of R^5 are F.

8. The compound of Claim 1 wherein R^5 is a substituted triazolyl-phenyl- group wherein:

(1)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: –$CH_2COH(CH_3)_2$, and -CH_2CH_2OH, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a –CH_3 group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one –CH_3 group, and on the carbon with one –CH_3 group, (f) said triazolyl moiety is optionally substituted on the carbon with a –NH_2 group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a –$CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with halo; or

(2)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with alkoxy; or

(3)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is substituted with halo; or

(4)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said

triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is substituted with alkoxy; or

(5)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with halo; or

(6)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with alkoxy; or

(7)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the

carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is substituted with halo; or

(8)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is substituted with alkoxy; or

(9)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is unsubstituted.

9. The compound of Claim 1 wherein R^5 is a substituted triazolyl-phenyl group wherein said triazolyl moiety is substituted with: (a) one substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) one alkyl group, (c) two alkyl groups, (d) one $-CH_3$ group, (e) two $-CH_3$ groups, (f) one $-NH_2$ group, or (g) one $-CH_2CH_2OCH_3$ group.

10. The compound of Claim 1 wherein the optional alkoxy substituents for the phenyl moiety of R^5 are $-OCH_3$.

11. The compound of Claim 1 wherein R^5 is selected from the group consisting of:

(a) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted with one or two alkyl groups selected from the group consisting of: -C_1-C_6alkyl, -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(b) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted with one or two alkyl groups selected from the group consisting of: -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(c) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted on the nitrogen with an alkyl group selected from the group consisting of: -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(d) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted on the nitrogen with an -alkylene-O-alkyl group selected from the group consisting of: -C_2-C_4alkylene-O-C_1-C_6alkyl, -C_2alkylene-O-C_1-C_2alkyl, -C_2-C_4alkylene-O-CH_3, and –$CH_2CH_2OCH_3$;

(e) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted on the nitrogen with an -alkylene-O-alkyl group selected from the group consisting of: -C_2alkylene-O-C_1-C_2alkyl, and –$CH_2CH_2OCH_3$;

(f) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted on the nitrogen with a hydroxy substituted alkyl group selected from the group consisting of: hydroxy substituted -C_1-C_4alkyl, hydroxy substituted -C_1-C_2alkyl, and hydroxy substituted -CH_3; and

(g) a substituted triazolyl-thienyl- wherein the triazolyl moiety is substituted on the nitrogen with a hydroxy substituted alkyl group selected from the group consisting of: $CH_2COH(CH_3)_2$, and -CH_2CH_2OH.

12. The compound of Claim 1 wherein R^5 is a substituted triazolyl-thienyl- group wherein:

(A)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: –$CH_2COH(CH_3)_2$, and -CH_2CH_2OH, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and

on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is optionally substituted with halo; or

(B)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is optionally substituted with alkoxy; or

(C)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is substituted with halo; or

(D)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$,

(b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is substituted with alkoxy; or

(E)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is optionally substituted with halo; or

(F)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is optionally substituted with alkoxy; or

(G)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is substituted with halo; or

(H)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is substituted with alkoxy; or

(I)




(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said thienyl moiety is unsubstituted.

13. The compound of Claim 1 wherein R^5 is a substituted triazolyl-thienyl group wherein said triazolyl moiety is substituted with: (a) one substituent selected from the group consisting of:–$CH_2COH(CH_3)_2$ and -CH_2CH_2OH, (b) one alkyl group, (c) two alkyl groups, (d) one –CH_3 group, (e) two –CH_3 groups, (f) one –NH_2 group, or (g) one –$CH_2CH_2OCH_3$ group.

14. The compound of Claim 1 wherein the optional alkoxy substituents for the phenyl moiety of R^5 are –OCH_3.

15. The compound of Claim 8 wherein R^1 is a pyridyl substituted with a substituent selected from the group consisting of: -O-CH_3, -O-C_2H_5, –O-$CH(CH_3)_2$, and –O-$(CH_2)_2$-O-CH_3, and R^2 is selected from the group consisting of: -OCH_3 and –SCH_3.

16. The compound of Claim 8 wherein R^1 is selected from the group consisting of:


,

, and

,

and R^2 is selected from the group consisting of: -OCH_3 and –SCH_3.

17. The compound of Claim 1 wherein:

(a) R^5 is a substituted triazolyl-pyridyl- wherein said triazolyl is substituted and said pyridyl is substituted; or

(b) R^5 is a substituted triazolyl-pyridyl- wherein said triazolyl is substituted on the nitrogen and said pyridyl is substituted; or

(c) R^5 is a substituted triazolyl-pyridyl- wherein said triazolyl is substituted on the carbon and said pyridyl is substituted; or

(d) R^5 is a substituted triazolyl-pyridyl- wherein said triazolyl is substituted on the nitrogen and on the carbon, and said pyridyl is substituted; or

(e) R^5 is a substituted triazolyl-pyridyl- wherein said triazolyl is unsubstituted and said pyridyl is substituted.

18. The compound of Claim 1 wherein:

(a) R^5 is a substituted triazolyl-pyridyl- wherein the triazolyl is substituted on the nitrogen with an alkyl group, and the pyridyl is unsubstituted; or

(b) R^5 is a substituted triazolyl-pyridyl- wherein the triazolyl is substituted on the nitrogen with an alkyl group and substituted on the carbon with an alkyl group, wherein each alkyl group is independently selected, and the pyridyl is unsubstituted; or

(c) R^5 is a substituted triazolyl-pyridyl- wherein the triazolyl is substituted on the nitrogen with a $-CH_3$ group, and the pyridyl is unsubstituted; or

(d) R^5 is a substituted triazolyl-pyridyl- wherein the triazolyl is substituted on the nitrogen with a $-CH_3$ group and on the carbon with a $-CH_3$ group, and the pyridyl is unsubstituted.

19. The compound of Claim 1 wherein:

(a) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted and said thiazolyl is unsubstituted; or

(b) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted on the nitrogen and said thiazolyl is unsubstituted; or

(c) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted on the carbon and said thiazolyl is unsubstituted; or

(d) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted on the nitrogen and on the carbon, and said thiazolyl is unsubstituted; or

(e) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted and said thiazolyl is substituted; or

(f) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted on the nitrogen and said thiazolyl is substituted; or

(g) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted on the carbon and said thiazolyl is substituted; or

(f) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is substituted on the nitrogen and on the carbon, and said thiazolyl is substituted; or

(h) R^5 is a substituted triazolyl-thiazolyl- wherein said triazolyl is unsubstituted and said thiazolyl is substituted.

20. The compound of Claim 1 wherein:

(a) R^5 is a substituted triazolyl-thiazolyl- wherein the triazolyl is substituted on the nitrogen with alkyl, and said thiazolyl is unsubstituted; or

(b) R^5 is a substituted triazolyl-thiazolyl- wherein the triazolyl is substituted on the nitrogen with an alkyl group and substituted on the carbon with an alkyl group, wherein each alkyl group is independently selected, and said thiazolyl is unsubstituted; or

(c) R^5 is a substituted triazolyl-thiazolyl- wherein the triazolyl is substituted on the nitrogen with a $-CH_3$ group, and said thiazolyl is unsubstituted; or

(d) R^5 is a substituted triazolyl-thiazolyl- wherein the triazolyl is substituted on the nitrogen with a $-CH_3$ group and on the carbon with a $-CH_3$ group, and said thiazolyl is unsubstituted.

21. The compound of Claim 1 wherein R^5 is a substituted pyridazinyl-thienyl- wherein said pyridazinyl is substituted and said thienyl is unsubstituted; or R^5 is a substituted pyridazinyl-thienyl- wherein said pyridazinyl is unsubstituted and said thienyl is substituted; or R^5 is a substituted pyridazinyl-thienyl- wherein said pyridazinyl is substituted and said thienyl is substituted.

22. The compound of Claim 1 wherein:

(a) R^5 is a substituted pyridazinyl-thienyl-wherein said pyridazinyl is substituted with a =O group, and said thienyl is unsubstituted; or


(b) R^5 is a substituted pyridazinyl-thienyl-wherein said pyridazinyl is substituted with an alkyl group, and said thienyl is unsubstituted; or


(c) R^5 is a substituted pyridazinyl-thienyl-wherein said pyridazinyl is substituted with a methyl group, and said thienyl is unsubstituted; or


In another embodiment of this invention R^5 is a substituted pyridazinyl-thienyl-wherein said pyridazinyl is substituted with a =O group, and with an alkyl group, and said thienyl is unsubstituted.


(d) R^5 is a substituted pyridazinyl-thienyl-wherein said pyridazinyl is substituted with a =O group, and with a methyl group, and said thienyl is unsubstituted.


23. The compound of Claim 1 wherein:













24. The compound of Claim 23 wherein R^1 is a pyridyl substituted with a substituent selected from the group consisting of: -O-CH_3, -O-C_2H_5, –O-$CH(CH_3)_2$, and –O-$(CH_2)_2$-O-CH_3, and R^2 is selected from the group consisting of: -OCH_3 and –SCH_3.

25. The compound of Claim 24 wherein R^1 is selected from the group consisting of:

















and R^2 is selected from the group consisting of: -OCH_3 and –SCH_3.


26. The compound of Claim 11 wherein the compound of formula 1.0 is a compound of formula 1.1:



(1.1)


27. The compound of Claim 26 wherein R^5 is selected from the group consisting of:













28. The compound of Claim 27 wherein R^1 is a pyridyl substituted with a substituent selected from the group consisting of: -O-CH_3, -O-C_2H_5, –O-$CH(CH_3)_2$, and –O-$(CH_2)_2$-O-CH_3, and R^2 is selected from the group consisting of: -OCH_3 and –SCH_3.

29. The compound of Claim 28 wherein R^1 is selected from the group consisting of:







30. The compound of Claim 1 wherein R^5 is selected from the group consisting of:





,

,

,

,

,

,

,

and

.




31. The compound of Claim 29 wherein R^5 is selected from the group consisting of:





,

,

,




32. The compound of Claim 1 wherein R^5 is selected from the group consisting of:











,

,

,





,

,

, and



.

33. The compound of Claim 29 wherein R^5 is selected from the group consisting of:


,

,

,

,


,

,

,



,

,

, and




34. The compound of Claim 1 wherein R^5 is triazolyl-phenyl-.

35. The compound of Claim 1 wherein R^5 is triazolyl-thienyl-.


36. The compound of Claim 1 wherein R^5 is




37. The compound of Claim 1 wherein R^5 is:




38. The compound of Claim 1 wherein R^5 is



39. The compound of Claim 1 wherein R^5 is



40. The compound of Claim 1 wherein R^6 is



41. A compound selected from the group consisting of compounds A1 to A16 and A18 to A30.

42. A compound selected from the group consisting of compounds A31 to A48.

43. The compound of Claim 41 wherein said compound is compound A1.

44. The compound of Claim 41 wherein said compound is compound A2.

45. The compound of Claim 41 wherein said compound is compound A3.

46. The compound of Claim 41 wherein said compound is compound A6.

47. The compound of Claim 41 wherein said compound is compound A7.

48. The compound of Claim 41 wherein said compound is compound A13.

49. The compound of Claim 41 wherein said compound is compound A19.

50. The compound of Claim 41 wherein said compound is compound A22.

51. The compound of Claim 41 wherein said compound is compound A24.

52. The compound of Claim 41 wherein said compound is compound A25.

53. The compound of Claim 41 wherein said compound is compound A27.

54. The compound of Claim 41 wherein said compound is compound A28.

55. The compound of Claim 41 wherein said compound is compound A29.

56. The compound of Claim 41 wherein said compound is compound A30.

57. A solvate, or a pharmaceutically acceptable salt, of a compound selected from the group consisting of compounds A1 to A16 and A18 to A48.

58. A pharmaceutically acceptable salt of a compound of Claim 41.

59. A solvate of a compound of Claim 41.

60. A solvate, or a pharmaceutically acceptable salt, of a compound of Claim 42.

61. The compound of Claim 1 in pure and isolated form.

62. The compound of Claim 41 in pure and isolated form.

63. The compound of Claim 42 in pure and isolated form.

64. A pharmaceutically acceptable salt of a compound of Claim 42.

65. A pharmaceutical composition comprising at least one compound of Claim 1 and a pharmaceutically acceptable carrier.

66. A pharmaceutical composition comprising at least one compound of Claim 41 and a pharmaceutically acceptable carrier.

67. A pharmaceutical composition comprising at least one compound of Claim 42 and a pharmaceutically acceptable carrier.

68. At least one compound of Claim 1 for use in the treatment of cancer.
69. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of cancer.
70. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of cancer.
71. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of cancer.
72. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent and an effective amount of radiation therapy for use in the treatment of cancer.
73. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent and an effective amount of radiation therapy in the manufacture of a medicament for the treatment of cancer.
74. At least one compound of Claim 1 and therapeutically effective amounts of at least one chemotherapeutic agent selected from the group consisting of: (1) taxanes, (2) platinum coordinator compounds, (3) epidermal growth factor (EGF) inhibitors that are antibodies, (4) EGF inhibitors that are small molecules, (5) vascular endolithial growth factor (VEGF) inhibitors that are antibodies, (6) VEGF kinase inhibitors that are small molecules, (7) estrogen receptor antagonists or selective estrogen receptor modulators (SERMs), (8) anti-tumor nucleoside derivatives, (9) epothilones, (10) topoisomerase inhibitors, (11) vinca alkaloids, (12) antibodies that are inhibitors of $\alpha V\beta 3$ integrins, (13) folate antagonists, (14) ribonucleotide reductase inhibitors, (15) anthracyclines, (16) biologies; (17) inhibitors of angiogenesis and/or suppressors of tumor necrosis factor alpha (TNF-alpha) such as thalidomide (or related imid), (18) Bcr/abl kinase inhibitors, (19) MEK1 and/or MEK 2 inhibitors that are small molecules, (20) IGF-1 and IGF-2 inhibitors that are small molecules, (21) small molecule inhibitors of RAF and BRAF kinases, (22) small molecule inhibitors of cell cycle dependent kinases such as CDK1 , CDK2, CDK4 and CDK6, (23) alkylating agents, and (24) farnesyl protein transferase inhibitors for use in the treatment of cancer.
75. The use of at least one compound of Claim 1 and therapeutically effective amounts of at least one chemotherapeutic agent selected from the group consisting of: (1) taxanes, (2) platinum coordinator compounds, (3) epidermal growth factor (EGF) inhibitors that are antibodies, (4) EGF inhibitors that are small molecules, (5) vascular endolithial growth factor (VEGF) inhibitors that are antibodies, (6) VEGF kinase inhibitors that are small molecules, (7) estrogen receptor antagonists or selective estrogen receptor modulators (SERMs), (8) anti-tumor nucleoside derivatives, (9) epothilones, (10) topoisomerase inhibitors, (11) vinca alkaloids, (12) antibodies that are inhibitors of $\alpha V\beta 3$ integrins, (13) folate antagonists, (14) ribonucleotide reductase inhibitors, (15) anthracyclines, (16) biologies; (17) inhibitors of angiogenesis and/or suppressors of tumor necrosis factor alpha (TNF-alpha) such as thalidomide (or related imid), (18) Bcr/abl kinase inhibitors, (19) MEK1 and/or MEK 2 inhibitors that are small molecules, (20) IGF-1 and IGF-2 inhibitors that are small molecules, (21) small molecule inhibitors of RAF and BRAF kinases, (22) small molecule inhibitors of cell cycle dependent kinases such as CDK1 , CDK2, CDK4 and CDK6, (23) alkylating agents, and (24) farnesyl protein transferase inhibitors in the manufacture of a medicament for the treatment of cancer.
76. At least one compound of Claim 1 in combination with at least one signal transduction inhibitor for use in the treatment of cancer.
77. The use of at least one compound of Claim 1 in combination with at least one signal transduction inhibitor in the manufacture of a medicament for the treatment of cancer.
78. At least one compound of Claim 1 for use in the treatment of cancer selected from the group consisting of: lung cancer, pancreatic cancer, colon cancer, myeloid leukemias, thyroid cancer, myelodysplasia syndrome, bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, prostate cancer, head and neck cancers, ovarian cancer, brain cancers, cancers of mesenchymal

origin, sarcomas, tetracarcinomas, myoblastomas, kidney carcinomas, hepatomas, non-Hodgkin's lymphoma, multiple myeloma, and anaplastic thyroid carcinoma.

79. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of cancer selected from the group consisting of: lung cancer, pancreatic cancer, colon cancer, myeloid leukemias, thyroid cancer, myelodysplasia syndrome, bladder carcinoma, epidermal carcinoma, mβlanoma, breast cancer, prostate cancer, head and neck cancers, ovarian cancer, brain cancers, cancers of mesenchymal origin, sarcomas, tetracarcinomas, myoblastomas, kidney carcinomas, hepatomas, non-Hodgkin's lymphoma, multiple myeloma, and anaplastic thyroid carcinoma.
80. At least one compound of Claim 1 for use in the treatment of cancer selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer.
81. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of cancer selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer.
82. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent, for use in the treatment of cancer selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer.
83. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of cancer selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer.
84. At least one compound of Claim 1 for use in the treatment of melanoma.
85. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of melanoma.
86. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of melanoma.
87. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of melanoma.
88. At least one compound of Claim 1 for use in the treatment of pancreatic cancer.
89. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of pancreatic cancer.
90. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of pancreatic cancer.
91. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of pancreatic cancer.
92. At least one compound of Claim 1 for use in the treatment of thyroid cancer.
93. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of thyroid cancer.
94. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of thyroid cancer.
95. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of thyroid cancer.
96. At least one compound of Claim 1 for use in the treatment of colorectal cancer.
97. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of colorectal cancer.
98. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of colorectal cancer.


99. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of colorectal cancer.
100. At least one compound of Claim 1 for use in the treatment of lung cancer.
101. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of lung cancer.
102. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of lung cancer.
103. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of lung cancer.
104. At least one compound of Claim 1 for use in the treatment of breast cancer.
105. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of breast cancer.
106. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of breast cancer.
107. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of breast cancer.
108. At least one compound of Claim 1 for use in the treatment of ovarian cancer.
109. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of ovarian cancer.
110. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of ovarian cancer.
111. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of ovarian cancer.
112. At least one compound of Claim 1 in combination with antihormonal agents, for use in the treatment of hormone-dependent breast cancer.
113. The use of at least one compound of Claim 1 in combination with antihormonal agents in the manufacture of a medicament for the treatment of hormone-dependent breast cancer.
114. At least one compound of Claim 1 in combination with antihormonal agents and in combination with an effective amount of at least one chemotherapeutic agent, for use in the treatment of hormone-dependent breast cancer.
115. The use of at least one compound of Claim 1 in combination with antihormonal agents and in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of hormone-dependent breast cancer.
116. At least one compound of Claim 1 for use in the treatment of brain cancer.
117. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of brain cancer.
118. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of brain cancer.
119. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of brain cancer.
120. At least one compound of Claim 1 in combination with an effective amount of temozolomide for use in the treatment of brain cancer.
121. The use of at least one compound of Claim 1 in combination with an effective amount of temozolomide in the manufacture of a medicament for the treatment of brain cancer.
122. At least one compound of Claim 1 for use in the treatment of prostate cancer.
123. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of prostate cancer.

124. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of prostate cancer.
125. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of prostate cancer.
126. At least one compound of Claim 1 for use in the treatment of myelodysplastic sybdrome.
127. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of myelodysplastic sybdrome.
128. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of myelodysplastic sybdrome cancer.
129. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of myelodysplastic sybdrome cancer.
130. At least one compound of Claim 1 for use in the treatment of myeloid leukemia.
131. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of myeloid leukemia.
132. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of myeloid leukemia.
133. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of myeloid leukemia.
134. At least one compound of Claim 1 for use in the treatment of acute myelogenous leukemia.
135. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of acute myelogenous leukemia.
136. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of acute myelogenous leukemia.
137. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of acute myelogenous leukemia.
138. At least one compound of Claim 1 for use in the treatment of chronic myelomonocytic leukemia.
139. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of chronic myelomonocytic leukemia.
140. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of chronic myelomonocytic leukemia.
141. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of chronic myelomonocytic leukemia.
142. At least one compound of Claim 1 for use in the treatment of chronic myelogenous leukemia.
143. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of chronic myelogenous leukemia.
144. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of chronic myelogenous leukemia.
145. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of chronic myelogenous leukemia.
146. At least one compound of Claim 1 for use in the treatment of bladder cancer.
147. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of bladder cancer.
148. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of bladder cancer.

149. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of bladder cancer.
150. At least one compound of Claim 1 for use in the treatment of non-Hodgkin's lymphoma.
151. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma.
152. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of non-Hodgkin's lymphoma.
153. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma.
154. At least one compound of Claim 1 for use in the treatment of multiple myeloma.
155. The use of at least one compound of Claim 1 in the manufacture of a medicament for the treatment of multiple myeloma.
156. At least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent for use in the treatment of multiple myeloma.
157. The use of at least one compound of Claim 1 in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the treatment of multiple myeloma.
158. At least one compound of Claim 1 in combination with antihormonal agents or at least one compound of Claim 1 in combination with antihormonal agents and in combination with an effective amount of at least one chemotherapeutic agent, for use in preventing hormone-dependent breast cancer.
159. The use of at least one compound of Claim 1 in combination with antihormonal agents or at least one compound of Claim 1 in combination with antihormonal agents and in combination with an effective amount of at least one chemotherapeutic agent in the manufacture of a medicament for the prevention of hormone-dependent breast cancer.

WHAT IS CLAIMED IS:


1. A compound of formula 1.0:



(1.0)

or a pharmaceutically acceptable salt or solvate thereof, wherein R^1, R^2 and Q are independently selected, and wherein:

Q is:



R^1 is selected from the group consisting of: heteroaryl and substituted heteroaryl, wherein said substituted heteroaryl is substituted with 1 to 3 substituents independently selected from the group consisting of: -OH, alkoxy, and –O-alkylene-O-alkyl;

R^2 is selected from the group consisting of: -O-alkyl and -S-alkyl; and


R^5 is selected from the group consisting of:

(a) triazolyl-phenyl-,

(b) triazolyl-phenyl- wherein said phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: halo and alkoxy, and

(c) substituted triazolyl-phenyl- wherein said phenyl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of: halo and alkoxy, and said triazolyl group is substituted with one or two substitutents independently selected from the group consisting of: alkyl, hydroxy substituted alkyl, -alkylene-O-alkyl, and amino, provided that when said -alkylene-O-alkyl group is bound to the nitrogen of said triazolyl in (c) the alkylene moiety of said -alkylene-O-alkyl group is not $–CH_2-$.

2. The compound of Claim 1 having the formula:



(1.1)

3. The compound of Claim 1 wherein R^5 is selected from the group consisting of:

(a) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted with one or two alkyl groups selected from the group consisting of: -C_1-C_6alkyl, -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(b) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted with one or two alkyl groups selected from the group consisting of: -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(c) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with an alkyl group selected from the group consisting of: -C_1-C_4alkyl, -C_1-C_2alkyl, and –CH_3;

(d) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with an -alkylene-O-alkyl group selected from the group consisting of: -C_2-C_4alkylene-O-C_1-C_6alkyl, -C_2alkylene-O-C_1-C_2alkyl, -C_2-C_4alkylene-O-CH_3, and –$CH_2CH_2OCH_3$;

(e) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with an -alkylene-O-alkyl group selected from the group consisting of: -C_2alkylene-O-C_1-C_2alkyl, and –$CH_2CH_2OCH_3$;

(f) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with a hydroxy substituted alkyl group selected from the group consisting of: hydroxy substituted -C_1-C_4alkyl, hydroxy substituted -C_1-C_2alkyl, and hydroxy substituted -CH_3;

(g) a substituted triazolyl-phenyl- wherein the triazolyl moiety is substituted on the nitrogen with a hydroxy substituted alkyl group selected from the group consisting of: $CH_2COH(CH_3)_2$, and -CH_2CH_2OH; and

(h) a substituted triazolyl-phenyl group wherein said triazolyl moiety is substituted with: (1) one substituent selected from the group consisting of:

$-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (2) one alkyl group, (3) two alkyl groups, (4) one $-CH_3$ group, (5) two $-CH_3$ groups, (6) one $-NH_2$ group, or (7) one $-CH_2CH_2OCH_3$ group.

4. The compound of Claim 3 wherein said compound is selected from the group consisting of: (a) to (g).

5. The compound of Claim 1 wherein: (a) the optional halo substituents for the phenyl moiety of R^5 are F; or (b) the optional alkoxy substituents for the phenyl moiety of R^5 are $-OCH_3$.

6. The compound of Claim 1 wherein R^5 is an optionally substituted triazolyl-phenyl- group; and wherein:

(1)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with halo; or

(2)

(a) said triazolyl moiety is optionally substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is optionally substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is optionally substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is optionally substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is optionally substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl

moiety is optionally substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with alkoxy; or

(3)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with halo; or

(4)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is optionally substituted with alkoxy; or

(5)

(a) said triazolyl moiety is substituted on the nitrogen with a substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) said triazolyl moiety is substituted on the nitrogen with an alkyl group, (c) said triazolyl moiety is substituted on the nitrogen with an alkyl group, and on the carbon with an alkyl group, (d) said triazolyl moiety is substituted on the nitrogen with a $-CH_3$ group, (e) said triazolyl moiety is substituted on the nitrogen with one $-CH_3$ group, and on the carbon with one $-CH_3$ group, (f) said triazolyl moiety is substituted on the carbon with a $-NH_2$ group, or (g) said triazolyl moiety is substituted on the nitrogen with a $-CH_2CH_2OCH_3$ group; and wherein said phenyl moiety is unsubstituted.


7. The compound of Claim 6 wherein R^5 is a substituted triazolyl-phenyl-group.

8. The compound of Claim 6 wherein said compound is a substituted triazolyl-phenyl wherein:

(a) R^1 is selected from the group consisting of:


(1) a pyridyl substituted with a substituent selected from the group consisting of: -O-CH_3, -O-C_2H_5, –O-$CH(CH_3)_2$, and –O-$(CH_2)_2$-O-CH_3;

(2)




;

(3)



; and

(4)




; and

(b) R^2 is selected from the group consisting of: -OCH_3 and –SCH_3.

9. The compound of Claim 1 wherein:

(a) R^5 is selected from the group consisting of:




and ;

(b) R^1 is selected from the group consisting of:


(1) a pyridyl substituted with a substituent selected from the group consisting of: -O-CH_3, -O-C_2H_5, –O-$CH(CH_3)_2$, and –O-$(CH_2)_2$-O-CH_3;

(2)




;

(3)



; and


(4)



; and


(c) R^2 is selected from the group consisting of: $-OCH_3$ and $-SCH_3$.

10. The compound of Claim 1 wherein R^5 is:



.


11. The compound of claim 1 or 2, wherein R^2 is $-OCH_3$, R^1 is:



and

R^5 is a substituted triazolyl-phenyl group wherein said triazolyl moiety is substituted with: (a) one substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) one alkyl group, (c) two alkyl groups, (d) one $-CH_3$ group, (e) two $-CH_3$ groups, (f) one $-NH_2$ group, or (g) one $-CH_2CH_2OCH_3$ group.


12. The compound of claim 1 or 2, wherein R^2 is $-SCH_3$, R^1 is:




and

R^5 is a substituted triazolyl-phenyl group wherein said triazolyl moiety is substituted with: (a) one substituent selected from the group consisting of: $-CH_2COH(CH_3)_2$, and $-CH_2CH_2OH$, (b) one alkyl group, (c) two alkyl groups, (d) one $-CH_3$ group, (e) two $-CH_3$ groups, (f) one $-NH_2$ group, or (g) one $-CH_2CH_2OCH_3$ group.


13. A compound selected from the group consisting of compounds A1 to A16 and A18 to A30, and pharmaceutically acceptable salts thereof, and compounds A31 to A48, wherein the structures of these compounds are as follows:



A1 ,




(A2) ,



(A3)


,



(A4)


,

5




(A5)


,




(A6),



(A7),




(A8),




(A9)

,




(A10)

,




(A11)


,




(A12) ,



(A13) ,




(A14) ,




(A15)

,




(A16)

,




(A18)


,




(A19),




(A20),



(A21),




(A22),




(A23)

,




(A24)

,




(A25)

,




(A26)

,




(A27)

,




(A28)


5 ,




(A29),




(A30),



(A31),




(A32),



(A33)


,



(A34)


,

5




(A35)

,




(A36)


,




(A37),




(A38),



(A39),




(A40),




(A41)

,




(A42)

,




(A43)

,




(A44)


,




(A45),



(A46),




(A47), and



(A48).

14. The compound of claim 13 which is:




(A6)

,

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 13 which is:




(A8)

,

or a pharmaceutically acceptable salt thereof.

16. The compound of claim 13 which is:




(A10)

,

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 13 which is:




(A25)

,

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 13 which is:




(A31)

,

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 13 which is:



,

or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising at least one compound of any previous Claim, or a pharmaceutically acceptable salt or solvent thereof and a pharmaceutically acceptable carrier.

21. A compound of any one of Claims 1 to 19, or a pharmaceutically acceptable salt or solvate thereof for use in therapy.

22. A compound of any one of Claims 1 to 19, or a pharmaceutically acceptable salt or solvate thereof for:

(a) use in treating cancer; or

(b) use in treating cancer wherein said compound is used with at least one chemotherapeutic agent; or

(c) use in treating cancer wherein said compound is used with at least one chemotherapeutic agent, and radiation therapy; or

(d) use in treating cancer wherein said compound is used with at least one chemotherapeutic agent selected from the group consisting of: (1) taxanes, (2) platinum coordinator compounds, (3) epidermal growth factor (EGF) inhibitors that are antibodies, (4) EGF inhibitors that are small molecules, (5) vascular endolithial growth factor (VEGF) inhibitors that are antibodies, (6) VEGF kinase inhibitors that are small molecules, (7) estrogen receptor antagonists or selective estrogen receptor modulators (SERMs), (8) anti-tumor nucleoside derivatives, (9) epothilones, (10) topoisomerase

inhibitors, (11) vinca alkaloids, (12) antibodies that are inhibitors of αVβ3 integrins, (13) folate antagonists, (14) ribonucleotide reductase inhibitors, (15) anthracyclines, (16) biologics; (17) inhibitors of angiogenesis and/or suppressors of tumor necrosis factor alpha (TNF-alpha) such as thalidomide (or related imid), (18) Bcr/abl kinase inhibitors, (19) MEK1 and/or MEK 2 inhibitors that are small molecules, (20) IGF-1 and IGF-2 inhibitors that are small molecules, (21) small molecule inhibitors of RAF and BRAF kinases, (22) small molecule inhibitors of cell cycle dependent kinases such as CDK1, CDK2, CDK4 and CDK6, (23) alkylating agents, and (24) farnesyl protein transferase inhibitors; or

(e) use in treating cancer wherein said compound is used with at least one signal transduction inhibitor; or

(f) use in treating cancer wherein said cancer being selected from the group consisting of: lung cancer, pancreatic cancer, colon cancer, myeloid leukemias, thyroid cancer, myelodysplastic syndrome, bladder carcinoma, epidermal carcinoma, melanoma, breast cancer, prostate cancer, head and neck cancers, ovarian cancer, brain cancers, cancers of mesenchymal origin, sarcomas, tetracarcinomas, nuroblastomas, kidney carcinomas, hepatomas, non-Hodgkin's lymphoma, multiple myeloma, and anaplastic thyroid carcinoma; or

(g) use in treating cancer wherein said cancer is selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer; or

(h) use in treating cancer wherein said compound is used with at least one chemotherapeutic agent, and wherein said cancer is selected from the group consisting of: melanoma, pancreatic cancer, thryroid cancer, colorectal cancer, lung cancer, breast cancer, and ovarian cancer; or

(i) use in treating cancer wherein said compound is used with antihormonal agents, and wherein said cancer is hormone-dependent breast cancer; or

(j) use in treating cancer wherein said compound is used with antihormonal agents, and with at least one chemotherapeutic agent, and wherein said cancer is hormone-dependent breast cancer; or

(k) use in treating cancer wherein said cancer is selected from the group consisting of brain cancer, prostate cancer, myelodysplastic syndrome, myeloid leukemia, acute myelogenous leukemia, chronic myelomonocytic leukemia, chronic

myelogenous leukemia, bladder cancer, non-hodgkin's lymphoma, multiple myeloma; or

(l) use in treating cancer wherein said compound is used with at least one chemotherapeutic agent, and wherein said cancer is selected from the group consisting of: brain cancer, prostate cancer, myelodysplastic syndrome, myeloid leukemia, acute myelogenous leukemia, chronic myelomonocytic leukemia, chronic myelogenous leukemia, bladder cancer, non-hodgkin's lymphoma, multiple myeloma; or

(m) use in treating cancer wherein said compound is used with temozolomide, and wherein said cancer is brain cancer; or

(n) use in preventing hormone-dependent breast cancer wherein said compound is used with antihormonal agents; or

(o) use in preventing hormone-dependent breast cancer wherein said compound is used with antihormonal agents, and with at least one chemotherapeutic agent.

23. Use of a compound of any one of Claims 1 to 19, or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for treating cancer.